Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]-Tebipenem Pivoxil Hydrobromide in Healthy Males
NCT04625855Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tebipenem in complicated urinary tract infection (cUTI) and acute pyelonephritis, sponsored by Spero Therapeutics. Primary endpoints: Pharmacokinetics of Tebipenem and Total Radioactivity. Started Sep 2020; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT04625855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625855.